Sign In
Buy IMMX
$8.32
-0.230 (-2.69%)
At Close: Jul 31, 2026
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded C
Immix Biopharma (IMMX) to Release Earnings on Monday
01:36am, Monday, 16'th Mar 2026
Immix Biopharma (NASDAQ: IMMX - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16)
Immix Biopharma to Participate in Upcoming Investor Conferences
08:45am, Tuesday, 03'rd Mar 2026
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
08:45am, Wednesday, 28'th Jan 2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting –
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
12:10am, Thursday, 11'th Dec 2025
Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing re
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
05:45pm, Tuesday, 09'th Dec 2025
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”,
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
06:20pm, Sunday, 07'th Dec 2025
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, tod
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
08:45am, Wednesday, 12'th Nov 2025
- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® -
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
02:39pm, Thursday, 06'th Nov 2025
Immix Biopharma has provided only faint early signals of its flagship CAR T-cell therapy in AL amyloidosis. However, an upcoming data presentation at ASH should shed more light on the prospects of a p
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
08:45am, Monday, 03'rd Nov 2025
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the glob
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
08:45am, Tuesday, 14'th Oct 2025
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, t
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
04:05pm, Monday, 06'th Oct 2025
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, t
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
08:45am, Wednesday, 01'st Oct 2025
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –
